Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Product sales	$ 8,226,992	$ 6,448,910
Cost of product sales	3,448,294	2,634,700
Gross profit	4,778,698	3,814,210
Operating expenses
Research and development	2,028,465	1,378,807
Sales and marketing	3,009,537	2,583,731
General and administrative	4,592,235	4,868,801
Total operating expenses	9,630,237	8,831,339
Operating loss	(4,851,539)	(5,017,129)
Other income (expenses)
Interest income	2,420	21,753
Interest expense, related party	(100,000)	0
Loss on deconsolidation of biologistex	(2,785,910)	0
Write off of deferred financing costs	(86,736)	0
Amortization of debt discount	(218,394)	0
Loss on disposal of property and equipment	(1,213)	0
Total other income (expenses)	(3,189,833)	21,753
Net Loss	(8,041,372)	(4,995,376)
Net Loss attributable to non-controlling interest	1,165,926	781,440
Net Loss attributable to BioLife Solutions, Inc.	$ (6,875,446)	$ (4,213,936)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc. (in dollars per share)	$ (0.54)	$ (0.35)
Basic and diluted weighted average common shares used to calculate net loss per common share (in shares)	12,642,996	12,177,396